tiprankstipranks
Advertisement
Advertisement
Diakonos Oncology Gains FDA Fast Track Status for Melanoma Therapy DOC1021
PremiumPrivate CompaniesDiakonos Oncology Gains FDA Fast Track Status for Melanoma Therapy DOC1021
18d ago
Early Glioblastoma Survival Data Highlight Potential for Diakonos Oncology Therapy
Premium
Private Companies
Early Glioblastoma Survival Data Highlight Potential for Diakonos Oncology Therapy
1M ago
Early Glioblastoma Survival Data Highlight Potential for Diakonos Oncology Therapy
Premium
Private Companies
Early Glioblastoma Survival Data Highlight Potential for Diakonos Oncology Therapy
1M ago
Diakonos Oncology Expands Phase 2 Glioblastoma Trial Across 14 U.S. Sites
PremiumPrivate CompaniesDiakonos Oncology Expands Phase 2 Glioblastoma Trial Across 14 U.S. Sites
2M ago
Diakonos Oncology Highlights Multi-Antigen Dendritic Cell Approach for Glioblastoma
Premium
Private Companies
Diakonos Oncology Highlights Multi-Antigen Dendritic Cell Approach for Glioblastoma
3M ago
Diakonos Oncology Highlights Multi-Antigen Immunotherapy Approach in Glioblastoma
Premium
Private Companies
Diakonos Oncology Highlights Multi-Antigen Immunotherapy Approach in Glioblastoma
3M ago
Diakonos Oncology Highlights Dendritic Cell Vaccines as Alternative Path in Solid Tumor Immunotherapy
PremiumPrivate CompaniesDiakonos Oncology Highlights Dendritic Cell Vaccines as Alternative Path in Solid Tumor Immunotherapy
4M ago
Diakonos Oncology Highlights Dendritic Cell Vaccine Strategy for Solid Tumor Immunotherapy
Premium
Private Companies
Diakonos Oncology Highlights Dendritic Cell Vaccine Strategy for Solid Tumor Immunotherapy
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100